Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815431 | 0.92 | SCN9A (0.38) | SCN9ASCN10A | |
| SCHEMBL14814865 | 0.89 | SCN9A (0.50) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL14833210 | 0.86 | ABL1 (0.42) | SCN9AKCNH2 | |
| SCHEMBL14815262 | 0.86 | ABL1 (0.42) | SCN9AKCNH2 | |
| SCHEMBL14815204 | 0.86 | ABL1 (0.42) | SCN9AKCNH2 | |
| SCHEMBL14833209 | 0.86 | ABL1 (0.42) | SCN9AKCNH2 | |
| SCHEMBL14815151 | 0.86 | SCN9A (0.43) | SCN9ASCN10AKCNH2LIPG | |
| SCHEMBL14815084 | 0.86 | SCN9A (0.42) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL14814943 | 0.86 | LIPG (0.43) | SCN9ASCN10ALIPG | |
| SCHEMBL14815093 | 0.85 | LIPG (0.43) | SCN9ASCN10ALIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | SCN9A 298/4885SCN10A 197/4885SCN7A 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.